Study: NCT02304679

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up questionnaires 1 month after Wave 1
Description: (Month 2)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires 3 months after Wave 1
Description: (Month 4)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up questionnaires 3 months after Wave 1
Description: (Month 4)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.~* The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 8 bi-weekly LIESWT (Wave 2) with the RENOVA device
Description: During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 8 bi-weekly LIESWT (Wave 2) with the RENOVA device
Description: During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up questionnaires 1 month after Wave 2
Description: (Month 6)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Follow-up questionnaires 1 month after Wave 2
Description: (Month 6)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires via postal mail
Description: Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires via postal mail
Description: Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Final follow-up questionnaires 12 months after Wave 2
Description: (Month 17)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Final follow-up questionnaires 12 months after Wave 2
Description: (Month 17)~During this visit the investigator will:~* Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.~* Perform a clinical exam; particular attention is given to the recording of complications / adverse events.